Posted by Michael Wonder on 19 Apr 2018
Four Canadian provinces add Erelzi (etanercept) to provincial drug plans for the treatment of multiple inflammatory diseases
19 April 2018 - Erelzi has been added to drug formularies in Manitoba, Saskatchewan, Alberta and Newfoundland based on specific criteria for the treatment of moderate to severe rheumatoid arthritis and for reducing signs and symptoms of active ankylosing spondylitis.
Manitoba, Saskatchewan, Alberta and Newfoundland are the most recent provinces to add Sandoz biosimilar Erelzi (etanercept) to provincial drug plans for the treatment of multiple inflammatory diseases.
The provincial listings respectively became effective on 19 April in Manitoba, 1 April 2018 in Saskatchewan, Newfoundland and on 1 March 2018 in Alberta. Sandoz biosimilar Erelzi was granted Health Canada approval in April 2017 and was launched in Canada in August 2017. Public access to Erelzi is also available in British Columbia, New Brunswick, Ontario, Prince Edward Island, Yukon and Quebec.
